Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 7;14(24):6026. doi: 10.3390/cancers14246026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Timeline from 1997 onwards, showing the development of therapeutics for B cell malignancies. (a) (1997–2020) Drugs currently approved by the FDA for the treatment of B cell malignancies; (b) investigational drugs in clinical development (2013–2021) for B cell malignancies. ADC, antibody–drug conjugate; BCL2, B-cell lymphoma/leukemia 2; BiTE, bispecific T-cell engager, BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor-T cells; PI3K, phosphatidylinositol-3 kinase.

Timeline from 1997 onwards, showing the development of therapeutics for B cell malignancies. (a) (1997–2020) Drugs currently approved by the FDA for the treatment of B cell malignancies; (b) investigational drugs in clinical development (2013–2021) for B cell malignancies. ADC, antibody–drug conjugate; BCL2, B-cell lymphoma/leukemia 2; BiTE, bispecific T-cell engager, BTK, Bruton tyrosine kinase; CAR-T, chimeric antigen receptor-T cells; PI3K, phosphatidylinositol-3 kinase.